| Identification | Back Directory | [Name]
2-Pyridinecarboxamide, 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-6-benzothiazolyl]oxy]-N-methyl-, hydrochloride (1:2) | [CAS]
2222138-40-9 | [Synonyms]
BLZ-945 2HCl
Sotuletinib dihydrochloride
2-Pyridinecarboxamide, 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-6-benzothiazolyl]oxy]-N-methyl-, hydrochloride (1:2) | [Molecular Formula]
C20H23ClN4O3S | [MOL File]
2222138-40-9.mol | [Molecular Weight]
434.94 |
| Hazard Information | Back Directory | [Uses]
Sotuletinib (BLZ945) dihydrochloride is an orally active and blood-brain barrier-permeable CSF1-R-specific inhibitor (IC50=1 nM). Sotuletinib (BLZ945) dihydrochloride induces tumor cell apoptosis and effectively inhibits tumor growth in mouse models. Sotuletinib dihydrochloride can be used in cancer and amyotrophic lateral sclerosis (ALS) research[1]. | [References]
[1] Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013 Oct;19(10):1264-72. DOI:10.1038/nm.3337
[2] Pognan F, et al. Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib. Curr Res Toxicol. 2022 Oct 29;3:100091. DOI:10.1016/j.crtox.2022.100091 |
|
|